XyclonyX

Xyclonyx is a private biotechnology company based in Hilden, Germany, focused on developing innovative biologics for the treatment of hard-to-treat solid tumors. Founded by Dr. Metin Colpan, a co-founder and former CEO of Qiagen, the company utilizes its proprietary Xy-body platform to engineer multi-specific antibodies designed to penetrate the dense stroma of the tumor microenvironment. These therapies aim to improve drug delivery and immune cell infiltration in cancers that are typically resistant to standard treatments, such as pancreatic adenocarcinoma. The company's lead candidate, XY-101, is currently in pre-clinical development and targets the CD44 antigen to modulate tumor growth and the surrounding matrix.